NAD(P)HX Dehydratase (NAXD) Deficiency — Comprehensive Disease Characteristics Report

Disease: NAD(P)HX Dehydratase Deficiency (PEBEL2) MONDO ID: MONDO:0034121 · OMIM (phenotype): #618321 · Gene: NAXD (HGNC:25576) Category: Mendelian (autosomal recessive inborn error of metabolite repair)

Summary

NAD(P)HX dehydratase (NAXD) deficiency — clinically designated PEBEL2 (Progressive Encephalopathy with Brain Edema and/or Leukoencephalopathy, type 2; OMIM #618321) — is an ultra-rare, autosomal-recessive inborn error of metabolite repair. It is caused by biallelic loss-of-function variants in NAXD, the gene encoding the ATP-dependent NAD(P)HX dehydratase (EC 4.2.1.93). Together with its partner enzyme NAD(P)HX epimerase (NAXE; the sister disorder PEBEL1), NAXD constitutes the intracellular NAD(P)HX repair system, which converts the toxic, non-functional hydrated forms of the redox cofactors NADH and NADPH (collectively NAD(P)HX) back to usable NAD(P)H. When NAXD is deficient, S-NADHX, R-NADHX and cyclic-NADHX accumulate and functional NAD(P)H is depleted, producing a cellular energy/redox crisis (PMID: 30576410; PMID: 34161859).

The defining clinical feature is a gene–environment interaction: the enzymopathy is often silent until a metabolic stressor — most commonly fever or infection, but also immunization, or physical trauma — sharply increases the non-enzymatic hydration of NAD(P)H and can denature thermolabile mutant enzyme. This precipitates acute, frequently fatal neurometabolic decompensation: rapidly progressive encephalopathy with brain and cerebellar edema and/or leukoencephalopathy, seizures, loss of developmental milestones, elevated CSF/serum lactate, characteristic flexural necrotic skin lesions, and — particularly for variants restricted to the mitochondrial isoform — cardiomyopathy and myopathy. Reported mortality across the combined NAXD/NAXE literature is approximately 78%, with survivors experiencing neurological sequelae (PMID: 39887790).

Critically, the disorder is at least partly treatable: niacin/nicotinamide (vitamin B3), which feeds NAD de novo / salvage synthesis and replenishes the depleted cofactor pool, improves skin lesions and survival in reported patients, providing a rational metabolic bypass therapy alongside aggressive control of febrile triggers (PMID: 39887790; PMID: 27616477; PMID: 38974613). This report synthesizes 9 confirmed findings across 18 papers into a complete disease knowledge-base entry.

Evidence-source note. This is an ultra-rare disease first defined in 2019; knowledge is derived almost entirely from aggregated case reports/series and functional studies (human clinical, patient fibroblasts/iPSCs, HAP1 knockouts, zebrafish, recombinant-enzyme biochemistry), not from population EHR or registry data. Fewer than ~20 genetically confirmed NAXD patients have been published. Where a claim rests on the sister disorder NAXE (PEBEL1) or on model systems, this is stated explicitly.

1. Disease Information

Overview. NAXD deficiency is a rare metabolite-repair disorder. NAD(P)HX dehydratase is a highly conserved enzyme essential for intracellular repair of the damaged/hydrated redox cofactor NAD(P)HX. As stated in the founding case series: "The highly conserved enzyme NAD(P)HX dehydratase (NAXD) is essential for intracellular repair of NAD(P)HX" (PMID: 30576410). Loss of the enzyme produces a fever-triggered neurodegenerative and multisystem disease.

Key identifiers.

The disease designation and OMIM ID are confirmed: "Encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy, 2 (PEBEL2; MIM# 618321), caused by biallelic pathogenic variants in the NAD(P)HX dehydratase (NAXD) is a rare metabolite repair disorder" (PMID: 34161859).

Synonyms / alternative names: PEBEL2; NAXD deficiency; NAD(P)HX dehydratase deficiency; carbohydrate kinase domain-containing protein deficiency (CARKD). The closely related sister disorder is NAXE deficiency / PEBEL1 (OMIM #617186), caused by the partner repair enzyme.

Information source. Knowledge derives predominantly from aggregated disease-level resources (OMIM, Orphanet, MONDO) and from individual patient case reports / small case series in the primary literature, supplemented by in vitro (cell line, recombinant enzyme) and model-organism (zebrafish) data. There is no large EHR-derived cohort; this is an ultra-rare disorder documented through gene-first (WES/WGS) discovery.

2. Etiology

Primary cause — genetic. The disease is caused by biallelic (homozygous or compound-heterozygous) loss-of-function variants in NAXD, inherited in an autosomal-recessive pattern. Biallelic NAXD variants were identified by whole-exome/whole-genome sequencing in a case series of infants and children with febrile-illness-induced neurodegeneration or cardiac failure and early death (PMID: 30576410). The molecular defect is a failure of an essential housekeeping "metabolite repair" function.

Genetic risk factors. The only established causal genetic factor is biallelic pathogenic NAXD variation. gnomAD constraint metrics (v2.1.1) are consistent with a recessive loss-of-function mechanism: pLI ≈ 5.5×10⁻⁵ (i.e., ~0, the gene tolerates heterozygous LoF) with observed/expected LoF (oe_lof/LOEUF) = 0.615 (95% CI 0.44–0.88). Carriers (heterozygotes) are asymptomatic.

Environmental "risk"/trigger factors. Uniquely, environment acts as the decompensation trigger rather than an independent cause. Documented triggers include febrile illness and infection (most common), routine immunization (PMID: 38214124), and physical/mechanical stress such as mild head trauma (PMID: 36834994). These raise body temperature and metabolic flux, accelerating non-enzymatic cofactor hydration and denaturing thermolabile mutant enzyme.

Protective factors. No genetic protective variants or modifier alleles have been defined. The main modifiable protective actions are avoidance/aggressive management of fever and triggers and niacin/nicotinamide supplementation (see Treatment).

Gene–environment interaction. This is a paradigmatic G×E disorder. The recombinant NAXD proteins bearing patient missense changes p.(Gly63Ser) and p.(Arg608Cys) were thermolabile with decreased Vmax and increased KM (PMID: 30576410) — providing a direct molecular explanation for why fever (a rise in body temperature) converts a compensated enzymopathy into an acute crisis. During stress, "nonenzymatic conversion of NAD(P)H to NAD(P)HX increases, and in the absence of repair, NAD(P)H is depleted, and NAD(P)HX accumulates, leading to decompensation" (PMID: 35637064).

3. Phenotypes

The phenotype spectrum spans neurological, cutaneous, cardiac, muscular and biochemical domains. Onset is typically in the first 1–3 years of life (median age of onset ~1.16 years across the combined cohort), though adult-onset is reported.

Characteristic cutaneous phenotype: "The characteristic skin eruption comprises well-demarcated erythematous and erosive plaques progressing to blistering and necrosis, predominantly affecting flexural surfaces" (PMID: 39887790).

Phenotypic diversity / atypical presentations. Not all patients show the full picture. One 7-month-old with a novel homozygous variant had neither preceding fever nor skin lesions, prompting the authors to note that "cases show phenotypic diversity" (PMID: 36158054). A patient presenting after routine immunizations had prominent skin findings in the absence of fevers (PMID: 38214124).

Quality-of-life impact. Formal QoL instruments (EQ-5D/SF-36) have not been applied to this ultra-rare disease. Qualitatively, the impact is profound: acute crises cause loss of acquired milestones, severe disability in survivors, and high early mortality.

4. Genetic / Molecular Information

Causal gene. NAXD (HGNC:25576; NCBI Gene 55739; Ensembl ENSG00000213995; gene-OMIM 615910), located at 13q34, encoding NAD(P)HX dehydratase (UniProt Q8IW45; EC 4.2.1.93). The sister gene is NAXE (HGNC:18453; Gene 128240; ENSG00000163382; 1q22; UniProt Q8NCW5; EC 5.1.99.6; phenotype-OMIM 617186; aliases APOA1BP/AIBP/YJEFN1).

Pathogenic variant spectrum. Variants are biallelic and predominantly missense, with frameshift/loss-of-function alleles also reported. Representative documented variants:

The founding study demonstrated loss of function at the protein level: "Recombinant NAXD protein harbouring two missense variants leading to the amino acid changes p.(Gly63Ser) and p.(Arg608Cys) were thermolabile and showed a decrease in Vmax and increase in KM for the ATP-dependent NADHX dehydratase activity" (PMID: 30576410).

Variant classification & population frequency. Reported variants are classified pathogenic/likely-pathogenic per ACMG (with occasional VUS such as p.Pro121Leu). Pathogenic alleles are exceedingly rare in gnomAD, consistent with a severe recessive disorder; heterozygous LoF is tolerated (pLI≈0), while biallelic LoF is disease-causing.

Functional consequence — loss of function (reduced/abolished enzymatic repair activity), not gain of function or dominant negative.

Isoform-determined genotype–phenotype correlation (modifier of expression). NAXD encodes two subcellular isoforms: "Exon 1 of NAXD contains a mitochondrial propeptide, and a unique cytosolic isoform is initiated from an alternative start codon in exon 2" (PMID: 35866541). The isoform hit by a given variant dictates phenotype: variants affecting both isoforms → neurological degeneration, seizures and skin lesions; variants affecting only the mitochondrial isoform → "myopathy, moderate neuropathy and a cardiac presentation, without the characteristic skin lesions, seizures or neurological degeneration" (PMID: 35866541).

Modifier genes / epigenetics / chromosomal abnormalities. No trans-acting modifier genes, epigenetic mechanisms, or large-scale chromosomal abnormalities have been implicated; the "modifier" of expression is the intragenic isoform architecture described above.

5. Environmental Information

• Environmental triggers (not toxins per se): febrile illness, infection, immunization, and physical/mechanical stress (e.g., mild head trauma). These accelerate the endogenous chemical damage reaction (NAD(P)H → NAD(P)HX). NAD(P)HX itself is described as "a toxic metabolite that is produced by stressors such as a fever, infection, or physical stress" (PMID: 38214124).
• Lifestyle factors: none established; disease presents in infancy/childhood. Relevant management is trigger avoidance and prompt antipyresis.
• Infectious agents: no specific pathogen causes the disease; any febrile infection can act as a non-specific trigger of decompensation.

6. Mechanism / Pathophysiology

Ordered causal chain

1. Biallelic loss-of-function variants in NAXD → loss of ATP-dependent NAD(P)HX dehydratase activity (demonstrated: thermolabile recombinant mutants with reduced Vmax/increased KM; PMID: 30576410).
2. Loss of repair capacity leads to failure to convert the damaged, hydrated cofactors back to NAD(P)H → accumulation of S-NADHX, R-NADHX and cyclic-NADHX and depletion of functional NAD(P)H (demonstrated in patient fibroblasts: "highly elevated concentrations of the damaged cofactors S-NADHX, R-NADHX and cyclic NADHX"; PMID: 30576410).
3. A metabolic stressor (fever/infection/immunization/trauma) results in an increased rate of non-enzymatic NAD(P)H hydration and denaturation of thermolabile mutant enzyme → an unrepaired surge in NAD(P)HX and acute cofactor depletion ("During stress, nonenzymatic conversion of NAD(P)H to NAD(P)HX increases…leading to decompensation"; PMID: 35637064).
4. This branches into downstream lesions:
5. 4a. Accumulated NAD(P)HX inhibits multiple dehydrogenases and NAD(P)H is depleted → impaired redox/energy metabolism → mitochondrial dysfunction (higher sensitivity to metabolic stress in galactose/azide media; PMID: 30576410).
6. 4b. Repair failure results in strong inhibition of the cytosolic, de novo serine synthesis pathway — a distinct, recently discovered downstream mechanism beyond mitochondrial impairment ("metabolomic analyses revealed a strong inhibition of the cytosolic, de novo serine synthesis pathway"; PMID: 39789421).
7. Combined energetic/redox and biosynthetic failure injures high-demand tissues → brain/cerebellum/white matter (encephalopathy, edema, leukoencephalopathy, seizures), heart/muscle (cardiomyopathy, myopathy), and skin (flexural erosive/necrotic lesions), with elevated CSF/serum lactate as a biochemical readout.
8. Untreated, the crisis progresses to coma, brain atrophy and death (~78% mortality); metabolic bypass with niacin/nicotinamide partially reverses the cofactor deficit and improves skin and survival.

Detail by category

• Molecular pathway / biochemical abnormality: defect in the NAD(P)HX repair (metabolite-repair) pathway; NAXD (EC 4.2.1.93) works with NAXE (EC 5.1.99.6). The hydrated cofactors are inhibitors of several dehydrogenases and generate harmful byproducts.
• Metabolic changes: depletion of the NAD(P)H redox pool; impaired energy metabolism; inhibition of de novo serine synthesis (PMID: 39789421); elevated lactate reflecting a shift toward anaerobic metabolism / mitochondrial impairment.
• Cellular processes: mitochondrial dysfunction; vulnerability under oxidative/metabolic stress (demonstrated by growth impairment in galactose vs glucose; PMID: 39789421, PMID: 30576410); neurodegeneration.
• Protein dysfunction: thermolability of mutant enzyme (mechanistic link to fever); reduced catalytic efficiency (↓Vmax, ↑KM).
• Immune involvement: zebrafish naxd knockouts reveal immune-system perturbations in early development (PMID: 41621837); clinically, infection/immunization acts as trigger, and inflammation likely amplifies cofactor-hydration stress.
• Tissue-damage mechanisms: metabolic/redox stress leading to cytotoxic edema, necrosis (skin), fibrosis (cardiac interstitial fibrosis; PMID: 39822994).

Suggested GO / CHEBI / CL terms: GO:0110051 (metabolite repair) / GO:0046496 (nicotinamide nucleotide metabolic process); GO:0052855 (ADP-dependent NAD(P)H-hydrate dehydratase activity, EC 4.2.1.93); GO:0006564 (L-serine biosynthetic process); GO:0005739 (mitochondrion, CC); GO:0005829 (cytosol, CC). CHEBI: NADHX, NADPHX, NAD(H), NADP(H), nicotinamide (CHEBI:17154), niacin (CHEBI:15940). CL: neuron (CL:0000540), cardiomyocyte (CL:0000746), keratinocyte (CL:0000312).

7. Anatomical Structures Affected

• Organ level (primary): brain and cerebellum (UBERON:0000955 brain; UBERON:0002037 cerebellum), cerebral white matter (UBERON:0002316), spinal cord (UBERON:0002240; myelopathy reported in the NAXE sister disorder). Skin (UBERON:0002097), predominantly flexural surfaces. Heart (UBERON:0000948) and skeletal muscle (UBERON:0001134) in cardiac/myopathic presentations.
• Body systems: central and peripheral nervous system, integumentary system, cardiovascular system, musculoskeletal system; respiratory insufficiency during crisis.
• Tissue/cell level: neurons and glia (white-matter/leukoencephalopathy → oligodendrocyte-supported myelin); cardiomyocytes (with interstitial fibrosis); keratinocytes/epidermis (necrotic skin lesions).
• Subcellular level: mitochondrion (GO:0005739) and cytosol (GO:0005829) — the two compartments corresponding to the mitochondrial and cytosolic NAXD isoforms; this compartmentalization directly maps to phenotype (Section 4).
• Lateralization: central lesions are typically bilateral/symmetric (edema, leukoencephalopathy); skin lesions are bilateral and flexural.

8. Temporal Development

• Onset: typically congenital-to-early-childhood, most within the first 1–3 years; median age of onset ~1.16 years in the combined NAXD/NAXE cohort (PMID: 39887790). Adult onset is possible: a 32-year-old presented after mild head trauma (PMID: 36834994).
• Onset pattern: characteristically (sub)acute decompensation superimposed on a previously well or mildly affected child, precipitated by a trigger.
• Progression: episodic-on-progressive — stepwise deterioration with each febrile/stress event, often rapidly progressive to coma and death without intervention. Between crises, patients may be relatively stable.
• Disease course / duration: frequently fatal in early childhood; survivors have chronic, lifelong neurological sequelae.
• Remission: no spontaneous cure; treatment-induced stabilization/improvement is reported with niacin/nicotinamide and trigger control.
• Critical periods / window of opportunity: the peri-febrile window is both the period of maximal vulnerability and the key intervention window — prompt antipyresis, supportive care and NAD-precursor supplementation.

9. Inheritance and Population

• Inheritance: autosomal recessive (biallelic NAXD variants). Both parents are asymptomatic carriers.
• Penetrance/expressivity: appears high penetrance in the biallelic state but variable expressivity — modulated by which isoform is affected (Section 4) and by exposure to triggers; some homozygotes present atypically without fever or skin lesions (PMID: 36158054).
• Epidemiology: ultra-rare; only case reports and small series (tens of patients worldwide across NAXD and NAXE). No reliable prevalence/incidence estimate exists; Orphanet lists it among ultra-rare metabolic disorders. A literature review compiled 45 NAXD/NAXE patients with 31 pathogenic/likely-pathogenic mutations (PMID: 39887790).
• Founder effects / consanguinity: homozygous variants in reported patients suggest a role for consanguinity in some families; no defined founder allele has been reported.
• Carrier frequency: not formally established; consistent with rarity, gnomAD shows very low pathogenic-allele frequencies.
• Population demographics / geography: cases reported across diverse populations (Europe, Middle East, Asia including China; a Chinese cardiomyopathy case is noted as "one of the few" in China; PMID: 39822994). No strong sex bias is established (both sexes affected). Age distribution skews to infancy/early childhood.

10. Diagnostics

Laboratory tests / biomarkers. - Elevated CSF and/or serum lactate is a key, reproducible biochemical clue (mild-to-marked; present in the NAXE sister disorder in all affected individuals: "Lactate was elevated in cerebrospinal fluid of all affected individuals"; PMID: 27616477). Basal metabolic tests may otherwise be near-normal (PMID: 36158054). - Definitive biomarker: markedly elevated damaged cofactors S-NADHX, R-NADHX and cyclic-NADHX in patient fibroblasts (research/specialized assay), abrogated by wild-type NAXD rescue (PMID: 30576410). - LOINC: lactate CSF (LOINC 2519-7), lactate plasma/serum (LOINC 2524-7 / 32693-4).

Imaging. Brain MRI showing cerebral/cerebellar edema, leukoencephalopathy, and (in progression) global brain atrophy is central to recognizing the acute encephalopathy.

Cardiac work-up. Echocardiography/cardiac MRI and endomyocardial evaluation may reveal metabolic cardiomyopathy with interstitial fibrosis in the absence of coronary disease or hypertension (PMID: 39822994).

Genetic testing (diagnostic gold standard). Diagnosis is molecular. Whole-exome or whole-genome sequencing identifies biallelic NAXD variants (the discovery and most subsequent diagnoses used WES/WGS; PMID: 30576410; PMID: 34161859). Targeted single-gene/panel testing (mitochondrial/leukodystrophy/metabolic-encephalopathy panels including NAXD and NAXE) is appropriate when the phenotype is suggestive. Segregation confirms biallelic status. Functional confirmation (fibroblast NAD(P)HX measurement or recombinant enzyme assay) can resolve VUS.

Clinical criteria / differential diagnosis. No formal consensus criteria exist; diagnosis rests on the triad of fever-triggered neuroregression + suggestive MRI (edema/leukoencephalopathy) + elevated lactate, confirmed genetically. Because it can be mistaken for a primary mitochondrial disease (patients have been treated with a "mitochondrial cocktail"; PMID: 36158054), key differentials include Leigh syndrome and other mitochondrial encephalopathies, other leukodystrophies, biotin-thiamine-responsive basal ganglia disease, and — with skin involvement — nutritional/genetic niacin-deficiency states (pellagra-like). The sister disorder NAXE deficiency (PEBEL1) is the closest differential and is distinguished by gene.

Screening. Not part of routine newborn screening. Cascade carrier testing of relatives and prenatal/preimplantation genetic testing are available once the familial variants are known.

11. Outcome / Prognosis

• Mortality: high — "The mortality rate was 78%, with survivors experiencing varying degrees of neurological sequelae" (PMID: 39887790). In the NAXE sister disorder, the course was rapidly progressive to coma, global brain atrophy and death.
• Morbidity/disability: survivors typically have significant neurological disability (developmental regression, spasticity, epilepsy, motor impairment).
• Prognostic factors: which isoform is affected (mitochondrial-only vs whole-cell) shapes organ involvement and course; frequency/severity of triggering events; and early institution of niacin/nicotinamide and trigger control, which improve skin lesions and survival. Niacin response, however, is not universal: one PEBEL1 patient deteriorated to a fatal outcome despite the highest reported niacin dose (PMID: 38974613).
• Complications: status epilepticus, respiratory failure, cardiac failure, secondary infections, and sequelae of brain injury.

12. Treatment

There is no curative therapy; management is metabolic bypass + aggressive trigger control + supportive care.

Pharmacotherapy / metabolic bypass. - Niacin / nicotinamide (vitamin B3) — the principal disease-modifying agent. By feeding NAD de novo/salvage synthesis it replenishes the depleted NAD(P) pool: "Niacin/nicotinamide supplementation resulted in improvements in skin lesions and survival rates" (PMID: 39887790). The rationale is explicit in the NAXE literature: "NAD or nicotinic acid (vitamin B3) supplementation might have therapeutic implications for this fatal disorder" (PMID: 27616477). A systematic review of 7 PEBEL1/PEBEL2 patients found most improved or stabilized on niacin, though one deteriorated fatally (PMID: 38974613). NCIT: niacin (NCIT:C574), nicotinamide (NCIT:C577). - Adverse-event management: niacin-related urticaria has been managed off-label with a COX-2 inhibitor (PMID: 38974613).

Acute supportive care. Prompt antipyresis and treatment of the precipitating infection, intensive supportive/neurocritical care during crises, seizure management, and cardiac support as needed. Empirical mitochondrial "cocktail" has been used but is not specifically corrective (PMID: 36158054).

Advanced / experimental therapeutics. No approved gene, cell, or RNA therapy exists. Wild-type NAXD lentiviral rescue corrects the biochemical defect in patient fibroblasts (proof of concept for gene replacement; PMID: 30576410). NAD-precursor strategies (nicotinamide riboside, nicotinic acid) are of mechanistic interest.

Personalized approach. Genotype (isoform affected) and trigger history should guide monitoring (e.g., cardiac surveillance for mitochondrial-isoform variants) and preventive planning.

13. Prevention

• Primary prevention: for at-risk families, genetic counseling, carrier testing, and reproductive options (prenatal/PGT) prevent recurrence. There is no population-level primary prevention (not vaccine-preventable; disease is genetic).
• Secondary prevention (trigger mitigation): in known-affected individuals, prompt and aggressive control of fever/infection, vigilance around immunizations and physical stress, and prophylactic niacin/nicotinamide aim to prevent decompensation. Caution and close monitoring are warranted around immunization given a reported post-vaccination decompensation (PMID: 38214124).
• Tertiary prevention: rehabilitation, epilepsy management, cardiac and respiratory support to limit complications in survivors.
• Counseling: autosomal-recessive recurrence risk is 25% per pregnancy for carrier couples; cascade testing of relatives is recommended.
• Screening: cascade carrier screening; prenatal diagnosis where familial variants are known. Not currently in newborn-screening panels.

14. Other Species / Natural Disease

• Evolutionary conservation: the NAD(P)HX repair system is ancient and highly conserved. NAXD/NAXE orthologs function in plants (Arabidopsis thaliana, Zea mays), E. coli, and vertebrates: "Arabidopsis thaliana and Zea mays NAD(P)HX dehydratase (NAXD) and NAD(P)HX epimerase (NAXE), two enzymes that are involved in repair of chemically damaged NAD(P)H cofactors" (PMID: 36710015).
• Orthologs / taxonomy (NCBI Taxon): human NAXD (Gene 55739); zebrafish naxd (used for CRISPR models; Danio rerio, taxon 7955); plant orthologs in A. thaliana (taxon 3702) and Z. mays (taxon 4577); bacterial yjeF-family in E. coli.
• Natural disease in other species: no spontaneously occurring NAXD-deficiency disease has been catalogued in companion animals/wildlife (no OMIA entry noted); relevance to date is via engineered models.
• Zoonotic potential: not applicable (genetic, non-transmissible).

15. Model Organisms

Zebrafish CRISPR evidence: "we generated zebrafish lines deficient in naxe or naxd using CRISPR/Cas9 technology. While both models accumulated NADHX, only naxd…" (PMID: 41621837). iPSC evidence: "we generated an induced pluripotent stem cell (iPSC) line from the dermal fibroblasts (HDFs) of a PEBEL2 patient who carried biallelic mutations, c.101_102delTA(p.Thr35Phefs63) and c.318C > G (p.Ile160Met) in NAXD"* (PMID: 38387170).

Model applications & limitations: these systems recapitulate the core NADHX accumulation and metabolic lesion and enable therapeutic testing; limitations include incomplete recapitulation of the full human multisystem/fever-triggered clinical phenotype and species-specific differences. Resources: ZFIN (zebrafish), Cellosaurus (HAP1, iPSC lines).

Mechanistic Model / Interpretation

 Biallelic LoF NAXD (recessive; gnomAD pLI≈0)
        │  loss of ATP-dependent NAD(P)HX dehydratase (EC 4.2.1.93)
        ▼
 Failure of NAD(P)HX repair
   ├── ↑ S-NADHX / R-NADHX / cyclic-NADHX  (toxic, inhibit dehydrogenases)
   └── ↓ functional NAD(P)H  (redox/energy pool depleted)
        │
   [ TRIGGER: fever / infection / immunization / trauma ]
        │  ↑ non-enzymatic NAD(P)H→NAD(P)HX  +  denatures thermolabile mutant enzyme
        ▼
 Acute unrepaired NAD(P)HX surge  →  metabolic decompensation
        ├──► Mitochondrial dysfunction  ─┐
        └──► ↓ de novo serine synthesis ─┤ combined energetic/biosynthetic failure
                                          ▼
        Injury to high-demand tissues:
        • Brain/cerebellum/white matter → encephalopathy, edema, leukoencephalopathy, seizures, ↑lactate
        • Heart/muscle → cardiomyopathy (interstitial fibrosis), myopathy   [esp. mito-isoform variants]
        • Skin (flexural) → erosive/necrotic plaques   [whole-cell deficiency]
        ▼
        ~78% mortality  ── niacin/nicotinamide (↑NAD synthesis) + trigger control → improved skin & survival

Upstream vs downstream: the NAXD mutation and cofactor-repair failure are upstream; mitochondrial dysfunction and serine-synthesis inhibition are parallel downstream effectors; tissue injury and clinical crisis are terminal. The fever/thermolability node is the key modifiable amplifier converting a compensated enzymopathy into acute disease, and the niacin bypass is the key therapeutic lever.

Evidence Base

Evidence source types: human clinical (case reports/series, literature reviews), in vitro (patient fibroblasts, HAP1 KO, recombinant enzyme, iPSC), model organism (zebrafish), and computational/genomic constraint (gnomAD).

Limitations and Knowledge Gaps

• Ultra-rare, no cohort epidemiology. Prevalence/incidence, carrier frequency, sex ratio, and penetrance estimates are unavailable; all clinical data come from small series prone to ascertainment/publication bias toward severe cases (mortality may be overestimated).
• Treatment evidence is anecdotal. Niacin/nicotinamide benefit is based on case reports and one small systematic review; there are no randomized trials, optimal dosing is undefined, and at least one patient deteriorated despite maximal therapy (PMID: 38974613).
• Mechanistic gaps. The relative contributions of mitochondrial dysfunction versus serine-synthesis inhibition to specific organ phenotypes are not resolved; why skin and cerebellum are especially vulnerable is unexplained; the immune-perturbation finding is model-derived and needs human validation.
• Genotype–phenotype nuance. The isoform rule explains broad patterns but individual variability (atypical fever-negative cases) indicates unidentified modifiers.
• No natural animal disease / limited long-term outcome data.

Proposed Follow-up Experiments / Actions

1. Establish an international patient registry to define natural history, prevalence, penetrance, sex ratio, and standardized outcomes; harmonize trigger and treatment data.
2. Prospective, dose-finding evaluation of NAD precursors (niacin, nicotinamide, nicotinamide riboside) with biochemical endpoints (NADHX/NAD(P)H, lactate) — ideally a basket trial spanning PEBEL1/PEBEL2.
3. iPSC-derived organoid modeling (neuronal, cardiac, keratinocyte) from BCHNDi001-A and new lines to test whether serine supplementation and NAD precursors rescue tissue-specific phenotypes (PMID: 38387170; PMID: 39789421).
4. Thermal-stress assays across the variant panel to build a genotype→thermolability→clinical-severity map, informing prognosis and trigger-avoidance counseling (PMID: 30576410).
5. Gene-replacement proof-of-concept in vivo (zebrafish naxd and/or AAV-NAXD in mammalian models), building on fibroblast lentiviral rescue.
6. Dissect the immune-perturbation phenotype from zebrafish in human systems to test whether inflammation independently amplifies decompensation (PMID: 41621837).
7. Develop a clinical NAD(P)HX/serine metabolite biomarker assay for rapid diagnosis and treatment monitoring, and evaluate inclusion of NAXD/NAXE in mitochondrial/leukodystrophy gene panels and consideration for newborn screening pilots.

Report compiled from 9 confirmed findings across 18 reviewed papers. All quoted material is verbatim from the cited PubMed abstracts.